Danaher (NYSE:DHR) Issues Earnings Results, Beats Estimates By $0.19 EPS

Danaher (NYSE:DHR) released its quarterly earnings results on Tuesday. The conglomerate reported $2.11 EPS for the quarter, topping the consensus estimate of $1.92 by $0.19, FiscalAI reports. The company had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.

Danaher Stock Up 0.2%

Danaher stock opened at $224.78 on Wednesday. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The stock has a 50 day moving average of $214.70 and a two-hundred day moving average of $196.54. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $158.02 billion, a price-to-earnings ratio of 39.93, a PEG ratio of 2.82 and a beta of 0.76.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Analysts Set New Price Targets

DHR has been the subject of a number of research reports. TD Cowen boosted their price objective on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Stifel Nicolaus lowered their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. The Goldman Sachs Group upped their price target on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Finally, Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Sunday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.